Literature DB >> 12146541

Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses.

Howard C Tenenbaum1, Avi Shelemay, Bruno Girard, Ron Zohar, Peter C Fritz.   

Abstract

Bisphosphonates are widely utilized in the management of systemic metabolic bone disease due to their ability to inhibit bone resorption. Recently, new uses of this unique class of pharmacological agents have been suggested. Given their known affinity to bone and their ability to increase osteoblastic differentiation and inhibit osteoclast recruitment and activity, there exists a possible use for bisphosphonates in the diagnosis and management of periodontal diseases. These bone-specific properties could also provide an interesting management strategy to stimulate osteogenesis in conjunction with regenerative materials around osseous defects and may also result in the promotion of bone formation around endosseous implants. The objective of this article is to review the scientific evidence regarding the potential applications of bisphosphonate drugs in the therapeutic management of periodontal diseases. Moreover, the mechanism of action and the pharmacology of these drugs will be reviewed. Finally, the potential role of bisphosphonates regarding their potential to accelerate bone formation, in addition to their usual uses for inhibition of bone resorption, is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12146541     DOI: 10.1902/jop.2002.73.7.813

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  13 in total

1.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

2.  Doxycycline effects on serum bone biomarkers in post-menopausal women.

Authors:  L M Golub; H-M Lee; J A Stoner; R A Reinhardt; T Sorsa; A D Goren; J B Payne
Journal:  J Dent Res       Date:  2010-03-26       Impact factor: 6.116

Review 3.  Developing siRNA therapies to address osteoporosis.

Authors:  Yuwei Wang; David W Grainger
Journal:  Ther Deliv       Date:  2013-10

4.  Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.

Authors:  S G Thakkar; C Isada; J Smith; M A Karam; J Reed; J W Tomford; K Englund; M Richmond; A Licata; C Hatch; M A Hussein
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 5.  Host-response therapeutics for periodontal diseases.

Authors:  William V Giannobile
Journal:  J Periodontol       Date:  2008-08       Impact factor: 6.993

6.  Effect of Alendronate with β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial.

Authors:  Rohini Naineni; Vishali Ravi; Dwijendra Kocherlakota Subbaraya; Jammula Surya Prasanna; Veerendranath Reddy Panthula; Rekha Rani Koduganti
Journal:  J Clin Diagn Res       Date:  2016-08-01

Review 7.  Host modulation therapy: An indispensable part of perioceutics.

Authors:  Minkle Gulati; Vishal Anand; Vivek Govila; Nikil Jain
Journal:  J Indian Soc Periodontol       Date:  2014-05

8.  Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine.

Authors:  Ying Gu; Clay Walker; Maria E Ryan; Jeffrey B Payne; Lorne M Golub
Journal:  J Oral Microbiol       Date:  2012-10-12       Impact factor: 5.474

9.  Effect of menopause on women's periodontium.

Authors:  Amit Bhardwaj; Shalu Verma Bhardwaj
Journal:  J Midlife Health       Date:  2012-01

Review 10.  Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.

Authors:  Lorne M Golub; Muna S Elburki; Clay Walker; Maria Ryan; Timo Sorsa; Howard Tenenbaum; Michael Goldberg; Mark Wolff; Ying Gu
Journal:  Int Dent J       Date:  2016-03-23       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.